首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2148754

牙周病治療市場：依藥物類型、通路和地區分類

Periodontal Disease Therapeutics Market, By Drug Type, By Distribution Channel, By Geography

出版日期: 2026年09月30日 | 出版商:

Coherent Market Insights | 英文 256 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，牙周病治療市場規模將達到 10.99 億美元，到 2033 年將達到 18.02 億美元。預計從 2026 年到 2033 年，該市場將以 7.3% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	10.99億美元
歷史數據時期：	2020年至2024年	預測期：	2026年至2033年
2026年至2033年預測期間的複合年成長率：	7.30%	2033年市場規模預測：	18.02億美元

該市場正經歷穩定成長，主要促進因素包括全球牙周病的高發生率、口腔健康管理意識的提高、輔助抗菌療法的日益普及以及局部給藥系統的進步。牙周治療，包括抗生素、局部抗菌劑、宿主調節劑和其他輔助療法，通常與傳統的機械性牙周治療方法（如齦上潔治和根麵平整術）合併使用。

疾病負擔的日益惡化是牙周治療需求成長的重要潛在促進因素。全球有超過10億人患有嚴重的牙周疾病，而全球整體口腔疾病患者總數已接近37億人。如此龐大的患者群體使得人們越來越需要有效的藥物和支持性干預措施，以控制感染、發炎、牙周袋深度以及支持組織的進行性喪失。

此外，市場正日益轉向局部緩釋給藥方式，這種方式可以將治療藥物直接輸送到牙周袋內，同時減少全身性藥物暴露。纖維、薄膜、尖端、微粒、凝膠、奈米顆粒和其他緩釋系統正被研究和應用，旨在提高抗菌活性、維持藥物釋放、減輕發炎並促進牙周組織再生。

市場動態

由於牙周疾病負擔沉重且持續存在，以及對有效支持性治療管理的需求不斷成長，全球牙周治療市場正蓬勃發展。牙周炎是一種慢性發炎性疾病，會影響支撐牙齒的組織和周圍骨骼，如果治療不當，會導致牙齒鬆動，最終甚至脫落。因此，隨著患者數量的增加，對抗生素、局部抗菌劑、宿主調節療法以及其他與機械牙周治療相結合的治療性介入的需求也持續成長。

擴大口腔健康服務覆蓋範圍並將牙科保健納入更廣泛的醫療保健體系，也是推動市場成長的因素。各國政府和全球衛生組織日益重視早期診斷、全面的口腔健康、與基層醫療的整合以及獲得必要的牙科治療。 2025年，世界衛生組織（世衛組織）制定了一項全球監測框架，其中包括2030年實現的11項口腔健康目標。同時，《曼谷宣言》強調進一步將口腔疾病納入全民健康納保（UHC）和初級衛生保健體系。這些努力有望改善牙周疾病的診斷和治療，進而提升對處方和輔助牙周治療的需求。

局部牙周治療技術的進步正在進一步塑造市場格局。緩釋製劑、局部給藥系統、奈米顆粒、奈米纖維、水凝膠和其他先進給藥平台的日益普及，使得在牙周袋內實現可控的治療濃度成為可能，同時最大限度地減少了全身暴露。此外，人們對抗生素抗藥性的日益關注，也推動了對非抗生素輔助性治療的研究，包括動態抗菌療法、褪黑素、次氯酸鈉凝膠、植物來源藥物和脂質體遞送方法。

專業牙科醫療基礎設施和牙周病治療系統的擴展也促進了市場發展。醫院、牙科診所、牙周病專科中心、零售藥局和線上藥局通路在獲得治療和藥品分銷方面發揮著至關重要的作用。預計在預測期內，牙科醫療覆蓋範圍的擴大和口腔健康服務成本效益的提高將推動早期診斷、治療啟動和處方箋牙周病治療藥物的更廣泛使用。

本次調查的主要特點

本研究揭示了各個細分市場的潛在商機，並為該市場說明了一個具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和批准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數對牙周病治療市場的主要參與者進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
本報告提供的見解將使企業行銷負責人和經營團隊能夠就未來的產品發布、產品類型升級、市場擴張和行銷策略做出明智的決策。
《牙周病治療市場》報告的目標受群眾外包括該行業的各種相關人員，例如投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以透過利用牙周病治療市場分析中使用的各種策略矩陣來簡化決策過程。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
歐洲
- 英國
- 德國
- 義大利
- 法國
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- ASEAN
- 澳洲
- 韓國
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 北非
- 中非
- 南非

第7章競爭情勢

熱圖分析
市佔率分析
公司簡介
- DenMat Holdings LLC.
- 3M
- Valeant Pharmaceuticals International, Inc.
- Galderma SA
- Dexcel Pharma Ltd.
- Kaken Pharmaceutical Co., Ltd.
- OraPharma Inc.
分析師意見

第8章

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI2022

Periodontal Disease Therapeutics Market is estimated to be valued at USD 1,099 Mn in 2026 and is expected to reach USD 1,802 Mn by 2033, growing at a compound annual growth rate (CAGR) of 7.3% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1,099 Mn
Historical Data for:	2020 to 2024	Forecast Period:	2026 to 2033
Forecast Period 2026 to 2033 CAGR:	7.30%	2033 Value Projection:	USD 1,802 Mn

The market is witnessing steady growth mainly driven by the high prevalence of periodontal disease globally, increasing awareness regarding oral health management, growing adoption of adjunctive antimicrobial therapies, and advancements in localized drug-delivery systems. Periodontal therapeutics, including antibiotics, locally administered antimicrobials, host-modulating agents, and other adjunctive treatments, are widely used alongside conventional mechanical periodontal procedures such as scaling and root planing.

The growing disease burden represents a significant underlying demand factor for periodontal treatment. Severe periodontal diseases affect more than 1 billion people worldwide, while the overall number of people affected by oral diseases is close to 3.7 billion globally. This substantial patient population is increasing the need for effective pharmacological and adjunctive interventions aimed at controlling infection, inflammation, periodontal pocket depth, and progressive loss of tooth-supporting tissues.

The market is also increasingly shifting toward localized and sustained-release drug-delivery approaches that enable therapeutic agents to be delivered directly into periodontal pockets while reducing systemic drug exposure. Fibers, films, chips, microparticles, gels, nanoparticles, and other controlled-release systems are being investigated and adopted for improved antimicrobial activity, prolonged drug release, inflammation reduction, and periodontal tissue regeneration.

Market Dynamics

The Periodontal Disease Therapeutics Market is gaining momentum owing to the substantial and persistent global burden of periodontal disease and increasing demand for effective adjunctive therapeutic management. Periodontitis is a chronic inflammatory condition affecting the supporting tissues and bone surrounding teeth and, if inadequately treated, can result in progressive tooth mobility and eventual tooth loss. The growing patient population is therefore supporting sustained demand for antibiotics, locally delivered antimicrobials, host-modulating therapies, and other therapeutic interventions used alongside mechanical periodontal treatment.

Expansion of oral healthcare access and integration of dental care into broader healthcare systems are also supporting market growth. Governments and international health organizations are increasingly emphasizing early diagnosis, comprehensive oral healthcare, primary-care integration, and access to essential dental treatment. In 2025, the World Health Organization developed a global monitoring framework incorporating 11 oral-health targets for 2030, while the Bangkok Declaration emphasized greater integration of oral diseases into universal health coverage and primary healthcare systems. Such initiatives are expected to improve periodontal disease diagnosis and treatment access, thereby supporting demand for prescription and adjunctive periodontal therapeutics.

Technological advancement in localized periodontal therapy is further shaping the market. The increasing adoption of sustained-release formulations, site-specific delivery systems, nanoparticles, nanofibers, hydrogels, and other advanced delivery platforms is enabling controlled therapeutic concentrations within periodontal pockets while minimizing systemic exposure. Furthermore, growing concern regarding antimicrobial resistance is encouraging research into non-antibiotic adjunctive therapies, including antimicrobial photodynamic therapy, melatonin, sodium hypochlorite gels, botanical agents, and liposome-based delivery approaches.

The expansion of specialist dental infrastructure and periodontal care capacity is also contributing to market development. Hospitals, dental clinics, specialist periodontal centers, retail pharmacies, and online pharmacy channels play important roles in treatment access and pharmaceutical distribution. Improved dental-care coverage and increasing affordability of oral-health services are expected to support earlier diagnosis, increased treatment initiation, and wider utilization of prescription periodontal therapies over the forecast period.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the Periodontal Disease Therapeutics Market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include DenMat Holdings LLC., 3M, Valeant Pharmaceuticals International, Inc., Galderma S.A., Dexcel Pharma Ltd., Kaken Pharmaceutical Co., Ltd., and OraPharma Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The Periodontal Disease Therapeutics Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Periodontal Disease Therapeutics Market

Market Segmentation

By Drug Type (Revenue, USD Mn, 2021-2033)
- Arestin
- Atridox
- Doxycycline
- Metronidazole
- Minocycline
- Periochip
- Others
By Distribution Channel (Revenue, USD Mn, 2021-2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Channel
By Region (Revenue, USD Mn, 2021-2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC
- Israel
- Rest of Middle East
- Africa
- South Africa
- Central Africa
- North Africa
Key Players
- DenMat Holdings LLC.
- 3M
- Valeant Pharmaceuticals International, Inc.
- Galderma S.A.
- Dexcel Pharma Ltd.
- Kaken Pharmaceutical Co., Ltd.
- OraPharma Inc.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Approval
Collaboration/Merge/Acquisition
Regulatory Landscape
PEST Analysis
Porter's Five Forces Analysis
Epidemiology
Robust Pipeline Analysis

4. Global Periodontal Disease Therapeutics Market, By Drug Type, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Arestin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Atridox
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Doxycycline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Metronidazole
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Minocycline
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Periochip
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

5. Global Periodontal Disease Therapeutics Market, By Distribution Channel, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
Online Channel
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)

6. Global Periodontal Disease Therapeutics Market, By Region, 2021 - 2033, (USD Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Type, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (USD Million)
  - North Africa
  - Central Africa
  - South Africa

7. Competitive Landscape

Heat Map Analysis
Market Share Analysis
Company Profile
- DenMat Holdings LLC.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- 3M
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Valeant Pharmaceuticals International, Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Galderma S.A.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Dexcel Pharma Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- Kaken Pharmaceutical Co., Ltd.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
- OraPharma Inc.
  - Company Highlights
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Market Strategies
Analyst Views